Clearbridge Investments LLC Acquires Shares of 190,064 Keros Therapeutics, Inc. (NASDAQ:KROS)

Clearbridge Investments LLC bought a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 190,064 shares of the company’s stock, valued at approximately $3,009,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Point72 Asset Management L.P. raised its position in Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after acquiring an additional 577,220 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Keros Therapeutics by 585.9% during the 4th quarter. JPMorgan Chase & Co. now owns 213,431 shares of the company’s stock worth $3,379,000 after purchasing an additional 182,314 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Keros Therapeutics by 5.4% in the 4th quarter. Vanguard Group Inc. now owns 1,957,109 shares of the company’s stock worth $30,981,000 after purchasing an additional 100,691 shares during the period. Emerald Advisers LLC lifted its stake in Keros Therapeutics by 57.3% in the fourth quarter. Emerald Advisers LLC now owns 244,633 shares of the company’s stock valued at $3,873,000 after purchasing an additional 89,088 shares during the last quarter. Finally, Janus Henderson Group PLC increased its position in Keros Therapeutics by 543.8% in the third quarter. Janus Henderson Group PLC now owns 92,110 shares of the company’s stock worth $5,354,000 after buying an additional 77,803 shares during the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on KROS. Oppenheimer cut their price target on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a research note on Thursday, January 16th. BTIG Research lowered shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. William Blair lowered shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 12th. Guggenheim reaffirmed a “neutral” rating on shares of Keros Therapeutics in a report on Friday, January 17th. Finally, Truist Financial reduced their price objective on shares of Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating for the company in a research note on Monday, December 23rd. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $42.33.

Keros Therapeutics Stock Performance

Keros Therapeutics stock opened at $10.28 on Friday. Keros Therapeutics, Inc. has a fifty-two week low of $9.41 and a fifty-two week high of $72.37. The stock has a market cap of $416.98 million, a P/E ratio of -1.97 and a beta of 1.39. The firm’s fifty day moving average price is $11.04 and its 200-day moving average price is $33.31.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.22. The business had revenue of $3.04 million for the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. Sell-side analysts predict that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.